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Introduction 
 
INTRODUCTION 
ANGIOGENESIS 
Angiogenesis is a physiological process involving the growth of new blood 
vessels from pre existing vessels. Though there has been some debate over this, 
vasculogenesis is the term used for spontaneous blood-vessel formation, and 
intussusception is the term for new blood vessel formation by splitting off existing 
ones. 
Types 
Sprouting angiogenesis 
Sprouting angiogenesis was the first identified form of angiogenesis. It occurs in 
several well characterized stages. First, biological signals known as angiogenic 
growth factors activate receptors present on endothelial cells present in pre-
existing veins. Second, the activated endothelial cells begin to release enzymes 
called proteases that degrade the basement membrane in order to allow 
endothelial cells to escape trom the original (parent) vessel walls. The endothelial 
cells then proliferate into the surrounding matrix and form solid sprouts 
connecting neighboring vessels. As sprouts extend toward the source of the 
angiogenic stimulus, endothelial cells migrate in tandem, using adhesion 
molecules, the equivalent of cellular grappling hooks, called integrins. These 
sprouts then form loops to become a full-fledged vessel lumen as cells migrate to 
the site of angiogenesis. Sprouting occurs at a rate of several millimeters per day, 
and enables new vessels to grow across gaps in the vasculature. It is markedly 
different from splitting angiogenesis, however, because it forms entirely new 
vessels as opposed to splitting existing vessels. 
Intussusceptive angiogenesis 
Intussusception, also known as splitting angiogenesis, was first observed in 
neonatal rats. In this type of vessel formation, the capillary wall extends into the 
lumen to split a single vessel in two. There are four phases of intussusceptive 
angiogenesis. First, the two opposing capillary walls establish a zone of contact. 
Second, the endothelial cell junctions are reorganized and the vessel bilayer is 
perforated to allow growth factors and cells to penetrate into the lumen. Third, a 
core is formed between the two new vessels at the zone of contact that is filled 
with pericytes and myofibroblasts. These cells begin laying collagen fibers into 
the core to provide an extracellular matrix for growth of the vessel lumen. Finally, 
the core is fleshed out with no alterations to the basic structure. Intussusception is 
important because it is a reorganization of existing cells. It allows a vast increase 
in the number of capillaries without a corresponding increase in the number of 
endothelial cells. This is especially important in embryonic development, as there 
are not enough resources to create a rich microvasculature with new cells every 
time a new vessel develops. 
 
Modern terminology of angiogenesis 
Besides the differentiation between "Sprouting angiogenesis" and 
"Intussusceptive angiogenesis" there exists the today more common 
differentiation between the following types of angiogenesis. 
 
Vasculogenesis - Formation of vascular structures from circulating or tissue-
resident endothelial stem cells (angioblasts), which proliferate into de novo 
endothelial cells. This form particularly relates to the embryonal development of 
the vascular system. 
 
Angiogenesis - Formation of thin - walled endothelium-lined structures 
with/without muscular smooth muscle wall and pericytes (fibrocytes). This form 
plays an important role during adult life span, also as "repair mechanism" of 
damaged tissues. 
 
Arteriogenesis - formation of medium - sized blood vessels possessing tunica 
media plus adventitia 
Because it turned out even this differentiation is not a sharp one, today quite often 
the term "Angiogenesis" is used summarizing all different types and 
modifications of artierial vessel growth. 
 
 
 
 
 
 
 
ANGIOGENESIS PROTEINS 
Stimulator Mechanism 
FGF Promotes proliferation & differentiation of 
endothelial cells , smooth muscle cells and 
fibroblasts  
VEGF Affects permeability 
VEGFR and NRP-1 Integrate survival signals 
Angl and Tie2 Stabilize vessels  
PDGF(BB-Homodimer) and PDGFR Recruit smooth muscle cells 
TGF-,endoglin and TGF – receptors  extracellular matrix production 
MCP-1  
Integrins v3, v5(?[9] ) and 51 Bind matrix macromolecules and 
proteinases 
VE-Catherin andCD31 Endothelial junctional molecules 
Ephrin Determine formation of arteries vein 
Plasminogen activators Remodels extra cellular matrix release and 
activates growth Factors  
Plasminogen activator inhibitor-1 Stabilize nearby vessels 
NOS and COX-2  
AC133 Regulate angioblast differentiation 
1d1 / 1d3 Regulates endothelial trans differentiation 
 
 
FGF (Fibroblast Growth Factor) 
The fibroblast growth factor (FGF) family with its prototype members FGF - 1 
(acidic FGF) and FGF - 2 (basic FGF) consists to date of at least 22 known 
members. Most are 16-18 kDa single chain peptides and display high affinity to 
heparin and heparin sulfate. In general, FGFs stimulate a variety of cellular, 
functions by binding to cell surface FGF - receptors in the presence of heparin 
proteoglycans. The FGF - receptor family is composed of seven members and all 
the receptor proteins are single chain receptor tyrosine kinases that become 
activated through autophosphorylation induced by a mechanism of FGF mediated 
receptor dimerization. Receptor activation gives rise to a single transudation 
cascade that leads to gene activation and diverse biological responses, including 
cell differentiation, proliferation, and matrix, dissolution - thus initiating a process 
of mitogenic activity critical for the growth of endothelial cells, fibroblasts, and 
smooth muscle cells. FGF -1, unique among all 22 members of the FGF family, 
can bind to all seven FGF - receptor subitypes, making it the broadest acting 
member of the FGF family, and a potent mitogen for the diverse cell types needed 
to mount an angiogenic response in damaged (hypoxic) tissues, where up 
regulation of FGF - receptors occurs. FGF- I stimulates the proliferation and 
differentiation of all cell types necessary for building an arterial vessel, including 
endothelial cells and smooth muscle cells, this fact distinguishes FGF -1 from 
other proangiogenic growth factors, such as vascular endothelial growth factor 
(VEGF) which primarily drives the formation of new capillaries. 
 
Until now (2007), three human clinical trials have been successfully completed 
with FGF -I in which the angiogenic protein was injected directly into the 
damaged heart muscle. Also, one additional human FGF-I trial has been 
completed to promote wound healing in diabetics with chronic wounds. 
 
Besides FGF-I, one of the most important functions of also fibroblast growth 
factor-2 (FGF-2 or bFGF) is the promotion of endothelial cell proliferation and 
the physical organization of endothelial cells into tube-like structures, thus 
promoting angiogenesis. FGF-2 is a more potent angiogenic factor than VEGF or 
PDGF (platelet-derived growth factor), however, less potent than FGF-l. As well 
as stimulating blood vessel growth, a FGF (FGF-I) and Bfgf (FGF-2) are 
important players in wound healing. They stimulate the proliferation of fibroblasts 
and endothelial cells that give rise to angiogenesis and developing granulation 
tissue, both increase blood supply and fill up a wound space/cavity early in the 
wound healing process. 
 
VEGF (Vascular Endothelial Growth Factor) 
VEGF (Vascular Endothelial Growth Factor) has been demonstrated to be a major 
contributor to angiogenesis, increasing the number of capillaries in a given 
network. Initial in Vitro studies demonstrated that bovine capillary endothelial 
cells will proliferate and show signs of tube structures upon stimulation by VEGF 
and b FGF, although the result were more pronounced with VEGF. Upregulation 
of VEGF is a major component of the physiological response to exercise and its 
role in angiogenesis is suspected to be a possible treatment in vascular injuries. 
 In vitro studies clearly demonstrate that VEGF is a potent stimulator of 
angiogenesis because in the presence of this growth factor plated endothelial cells 
will proliferate and migrate, eventually forming tube structures resembling 
capillaries. VEGF causes a massive signaling cascade in endothelial cells. 
Binding to VEGF receptor -2 (VEGFR-2) starts a tyrosine kinase signaling 
cascade that stimulates the production of factors that variously stimulate vessel 
permeability (eNoS, producing NO), proliferation/survival (Bfgf), migration 
(ICAMSNCAMs/MMPs) and finally differentiation into mature blood vessels. 
Mechanically, VEGF is upregulated with muscle contractions as a result of 
increased blood flow to affected areas. The increased flow also causes a large 
increase in the m RNA production of VEGF receptors 1 and 2. The increase in 
receptor production means that muscle contractions could cause upregulation of 
the signaling cascade relating to angiogenesis. As part of the angiogenic signaling 
cascade, NO is widely considered to be a major contributor to the angiogenic 
response because inhibition of NO significantly reduces the effects of angiogenic 
growth factors. However, inhibition of NO during exercise does not inhibit 
angiogenesis indicating that there are other factors involved in the angiogenic 
response. 
 
Angiopoietins 
The angiopoietins, Angl and Ang2, are required for the formation of mature blood 
vessels, as demonstrated by mouse knock out studies. Angl I and Ang 2 are 
protein growth factors which act by binding their receptors. Tie-l and Tie-2, while 
this is somewhat controversial, it seems that cell signals are transmitted mostly by 
Tie-2, though some papers show physiologic signaling via Tie-l as well. These 
receptors are tyrosine kinases. Thus, they can initiate cell signaling when ligand 
binding causes a dimerization that initiates phosphorlation on key tyrosines. 
 
MATRIX METALLO PROTEINASE  
Another major contributor to angiogenesis is matrix metallo proteinase (MMP). 
MMPs help degrade the proteins that keep the vessel walls solid. This proteolysis 
allows the endothelial cells to escape into the interstitial matrix as seen in 
sprouting angiogenesis. Inhibition of MMPs prevents the formation of new 
capillaries. These enzymes are highly regulated during the vessel formation 
process because destruction of the extracellular matrix would decrease the 
integrity of the microvasculature. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Aim of the Study 
 
  
 
 
 
 
 
 
AIM OF THE STUDY 
 
To evaluate the safety and efficacy of intravitreal Bevacizumab in the 
management of various retinal vascular diseases. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Review of Literature 
 
 
REVIEW OF LITERATURE 
Many retinal diseases occur due to abnormal angiogencsis, these include vascular 
disorders such as Diabetic Retinopathy, Vein Occlusions and Age related Macular 
Degeneration. 
A) DIABETIC RETINOPATHY 
Diabetic retinopathy is a leading cause of severe loss of visual acuity in developed 
countries. About 25 % of diabetic patients have sight threatening levels of 
retinopathy with legal blindness. 
ETIOPATHOGENESIS 
 
The exact cause of diabetic microvascular disease is unknown. It is believed that 
exposure to hyperglycemia over extended period results in a number of 
biochemical and physiologic changes that ultimately cause vascular endothelial 
damage. 
Pathogenesis of Microvascular occlusion  
1. Basement membrane thickening 
2. Damage and proliferation of endothelial cells 
3. Increased erythrocyte aggregation leading to defective oxygen transport. 
4. Increased platelet adhesiveness 
5. Abnormal levels of growth hormones such as Vaso Endothelial Growth 
Factor 
6. Defective fibrinolysis 
7. Abnormal serum lipids 
8. Increased blood viscosity 
Pathogensis of Microvascular Leakage (Jack J. Kanski, 5th Edition, p.no 440) 
1. Breakdown of inner blood retinal barrier (i.e tight junctions of capillary 
endothelium) 
2. Loss of pericytes leads to physical weakening of capillary wall resulting in 
localized vascular outpouchings termed micro aneurysms which may leak 
or become thrombosed 
SIMPLE BACKGROUND DIABETIC RETINOPATHY 
CLINICAL FEATURES 
1. Microaneurysms 
2. Intraretinal haemorrhages 
3. Hard exudates 
4. Retinal oedema 
MANAGEMENT 
Eyes with simple background Diabetic Retinopathy not associated with clinically 
significant macular oedema do not require laser treatment. 
CLINICAL FEATURES OF DIABETIC MACULAR EDEMA 
It is the most common cause of visual impairment in diabetic patients, particularly 
those with type II diabetes.  
Focal Exudative 
Signs: Well circumscribed retinal thickening associated with complete or 
incomplete rings of hard exudates derived from plasma lipoprotein that appears to 
emanate from microaneurysms. 
Fundus Fluorescein Angiography (FFA): Shows late focal hyperfluorescence due 
to leakage and good macular perfusion. 
Diffuse Exudative 
Signs: Diffuse retinal thickening, which may be associated with cystoid changes. 
FFA: Shows widespread spotty hyperfluorescence of micro aneurysm and late 
diffuse hyperfluorescence due to leakage. Flower petal pattern is seen in case of 
cystoid macular edema. 
Ischemic 
Signs: Reduced visual acuity with a relatively normal appearance of fovea. Dark 
blot hemorrhages may be seen. 
FFA: Shows capillary non perfusion at the fovea and enlargement and irregularity 
of foveal avascular zone (FAZ) 
Mixed 
Signs: Characterized by features of both ischemic and exudative. 
Chinical Significant Macular Edema (CSME) 
ETDRS defined clinically significant macular edema as anyone of the following. 
I. Retinal edema located at or within 500µ  of the center of the macula. 
II. Hard exudates at or within 500µ  of the center of associated with thickening 
of adjacent retina. 
III. A zone of retinal thickening larger than 1 disc area if located within 1 disc 
diameter of the centre of the macula. 
 CSME requires laser photocoagulation irrespective of the level of visual acuity 
because treatment reduces the risk of visual loss by 50%. 
 Adamis et al., have studied that features of chronic inflammation such as adhesion 
of leucocytes to the retinal vasculature and migration into retina, may playa role 
in diabetic maculopathy and retinopathy. 
 
 Preproliferative diabetic retinopathy 
 CLINICAL FEATURES 
1. Vascular changes 
2. Cotton - wool spots 
3. Dark blot haemorrhages 
4. lntraretinal microvascular abnormalities 
  MANAGEMENT 
 Patients with preprolifertative changes should be watched closely because a 
significant number develop proliferative Diabetic Retinopathy. Treatment by 
photocoagulation is usually unnecessary unless regular follow - up is impossible, 
especially if the patient has lost sight in the fellow eye from complications of 
proliferative Diabetic Retinopathy. 
 Proliferative diabetic retinopathy 
 CINICAL FEATURES 
1. Neovascularization 
2. Vitreous detachment 
3. Haemorrhage 
 
 
 
INDICATIONS FOR TREATMENT 
The indication for treatment depends on the risk of subsequent severe visual loss. 
The following are the clinical features of eyes at high risk: 
a) NVD or neovascularization within one disc diameter of the optic disc 
more than one quarter disc in area. 
b) Less extensive NVD, if associated with vitreous or preretinal 
haemorrhage. 
c) NVE more than one - half disc in area if associated with vitreous or 
preretinal haemorrhage. 
B. RETINAL VEIN OCCLUSIVE DISEASE 
RETINAL VEIN OCCLUSIVE DISEASE 
Predisposing Factors    Pathogenesis  
Common                                                                     Athersclerosis (BRVO) 
1. Advancing Age    Retinal arteriole & vein share 
2. HTN     Common adventitious sheath  
3. Hyperlipidemia    Thickening of sheath 
4. Diabetes mellitus    Compres the vein  
5. Raised IOP     20 Changes 
Uncommon      - Vein endothelial loss 
1. Myeproliferative Disorders   - Thrombus formation 
2. Acquired Hypercoaguable states  - Occlusion 
3. Inherited Hyper coaguable states   
4. Inflammatory disease associated with Occulusive periphletitis 
BRANCH RETINAL VEIN OCCLUSION 
CLASSIFICATION 
1. Major BRVO 
- First Order Temporal Branch at the optic Disc 
- First Order Temp Branch away from the Disc but involving the 
branches to the Macula. 
2. Minor Macular BRVO 
  - Involving only a Macular Branch 
3. Peripheral BRVO 
  - Not involving the Macular circulation 
 Diagnosis 
1. Presentation   Sudden Onset of Blurred Vision and Metamorphopsia 
or a relative Visual field defect. 
2. Visual Activity is Variable 
3. Fundus  Dilatation and Tortusity of Veins distal to the site of 
Occlusion and attenuation/Flame shaped, and Dot & Blot Hge, retinal 
oedema & cotton wool spot. 
4. FA  Shows delayed Vein filling, hyperfluoroscene due to leakage, 
hypofluoroscence due to Capillary non – perfusion. 
5. Course  Acute Features (6-12 Months) 
- Hard Exudates, Vein Sheathing and sclerosis peripheral to the site of 
Obstruction 
- Collateral Vein channels between the superior & Inferior vascular 
Arcades 
Prognosis 
  - The two main Vision threatening Complications are 
i) Chronic Macular oedema 
       NVD - 10 % 
ii) Neovascularization ---- 
        NVE  - 25 % 
 Follow Up  is within 6 – 12 Weeks within FA 
 Further treatment depends on Visual Acuity and angiographic findings as follows 
• Good macular perfusion and Visual Acuity is improving, No Treatment 
• Macular oedema is asstd with good macular Perfusion and Visual Acuity 
Continues to be 6/12 or, worse Laser Photocoagulation should be Considered 
• If FA shows Foveal Avascular Zone is broken, laser is less likely to improve 
Visual Acuity Macular Non Perfusion and Visual Acuity is Poor, Laser 
treatment will not improve Vision 
 Treatment 
1. Macular Ocdema 
a) Grid Laser Photocoagulation 100 -200 µ 
   0.1 Sec 
b) Intra Vitreal Avastin may improve Visual Acuity 
2. Neovascularization is normally treated unless Vitreous Hge Occurs 
Laser Photocoagulation 200 – 300 µ 
   0.5 – 0.1 Sec 
A quadrant usually requires 400 - 500 burns  
Follow up Should be after 4 – 6 Weeks 
Non ISCHAEMIC Central Retinal Vein Occlusion 
Non ISCHAEMIC Central Retinal Vein Occlusion accounting 75% of all cases. 
Diagnosis 
- Sudden U/L Blurred Vision 
- Visual Acuity is impaired to moderate – severe 
- Afferent Pupillary Defect is absent or mild 
Fundus 
• Tortuous and dilatation of all branches of Central Retinal Vein , Dot & Blot 
Hge, Flame shaped Hge throught all 4 quadrants 
• Cotton wool spot, optic disc and macular ocdema 
FA shows delayed A – V transit time, good retinal capillary perfusion and late 
leakage  
Course  
- Most acute signs resolve Over 6 – 12 months 
PROGNOSIS 
- In case do not subsequently become Ischaemic the  
prognosis is good 
- The main causes for poor vision is chronic macular oedema 
TREATMENT 
Laser Photocoagulation for macular ocdena is not beneficial 
Following Therapies 
1. Cannulation (TPA) 
2. Intravitreal Avastin for Cystoid Macular Oedema 
3. Optic Nerve Sheathotomy 
ISCHAEMIC Central Retinal Vein Occlussion 
Venus Obstruction 
Retinal Perfusion + Capillary Closure + Retinal Hypoxia 
Retinal Ischaemic 
Neo Vascular Glaucoma 
DIAGNOSIS 
Presentation  Sudden and severe Visual Impairment 
Visual Acuity  Counting Fingers 
Afferent pupillary defect  Marked 
FUNDUS 
• Tortuous and engorgement of all branches of Central Retinal Vein; Extensive 
Dot & Blot Hge Flame Shaped Hge, Severe optic disc oedema + hyperaemia 
• Cotton wool spots 
FLUOROESCEIN ANGIOGRAPHY  Delay in A - V Transit time, Central 
masking by retnal Hge, Extensive areas of capillary non perfusion 
ERG   is decreased 
COURSE  Most acute signs resolve in 9 – 12 months 
Residual findings  disc collaterals + Macular epiretinal gliosis + Pigmentary 
changes 
PROGNOSIS 
- Prognosis is poor due to Macular Ischaemia 
- RUBEOSIS IRIDIS 
( 2 -4 months) 100 day glaucoma 
- Unless Vigrous Pan Retinal Photocoagluation is performed 
there is high risk of Neo Vascular Glaucoma 
TREATMENT 
- Laser Pan Retinal Photocoagluation should be performed 
in Rubeosis Iridis 
- Application of 1500 – 3000 burns 
- 0.5   0.1 Sec 
 
C. AGE RELATED MACULAR DEGENERATION 
I. INTRODUCTION 
1. Definition 
a. Age Related Maculopathy Aging Process Characterised by 
DRUSEN + Hyperpigmentation or depigmentation of RPE 
b. Age related Macular Degeneration  Geographical Atrophy + 
Pigment Epithelial Detachment + Choroidal New Vessels + Fibroglial 
Scar 
2. Risk Factors 
(a) Age  (b) ARM   (c)Race (d) Family H/o (e) Cataract 
3. DRUSEN Abnormal material in Bruch’s membrane and basal lamina of 
RPE(Yellow excesences beneath the RPE)  
Types 
(Small Hard /Large Soft / Drusenoid RPE detachment/Calcified) 
FA  Hyperfluorescence is due to atroppy of RPE (hydrophilic) 
 Hyperfluoscence – hydrophobic lowlipid content 
DD - Familial Dominant Drusen 
- Hard exudates 
- Type 3 Membranoproliferative glomeuronephritis 
II. Atrophic Age related Macular Degeneration 
DRY Age Related Macular degeneration  Atrophy of photoreceptor + RPE + 
Choriocapillaries. 
Signs   Focal Atrophy of RPE 
Loss of choriocapillarics 
Enlargement of the Atrophic Areas 
With the larger choroidal vessels 
FA   Hyperfluoroscence  
Due to unmaking of background choridal Fluorescence 
Treatment  LVA(Low vision Aids) 
III. Retinal Pigment Epithelium Detachment 
Pigment Epithelium Detachment 
Caused by reduction of Hydraulic conductivity of Bruch’s Membrane 
Signs Dome shaped elevation 
Sub RPE fluid is clear or Turbid 
FA  Demarcated Oval area of Hyperfluroscence due to pooling of dye under the 
detachment 
OCT  Separation of RPE from Bruch’s membrane  by fluid 
COURSES 
- Spontaneous Resolution 
- Geographic Atrophy 
- Detachment of the Sensory Retina 
- RPE Tear formation  
 
 
 
 
IV. RETINAL PIGMENT EPITHELIAL TEAR 
A tear of RPE may occur at the junction of attached and detached RPE, Tears may 
occur Spontanously following laser Photocoagulation of CNV 
Signs  Crescent Shaped RPE dehiscence 
FLUOROSCEIN ANGIOGRAPHY   
I. CNV in the early phase  
II. Late Phase  Hypoflouroscence (flap folded over & 
thickened RPE  
III. Hyperfluoroscence  Exposed choriocapillares 
OCT 
- Loss  of the normal dome shaped profile of the RPE in 
Pigment Epethelium Detachment 
Prognosis 
- Poor in subfoveal tears 
V. NEOVASCULAR ARMD 
Pathogenesis 
- Neovascular ARMD caused by Choroidal New Vessels 
originated from the choriocapillaries through the defects in 
Bruch’s membrane 
- Intial visual loss associated CNV caused by blood under 
the Retina (SRF), into the retina (Macular odema) and 
under the RPE (PED) 
Clinical Features 
Presentation  Positive Scotomata & blurring of Vision due to fluid leakage 
from CNV 
Signs 
- Sub RPE (type1) CNV appears as grey – green 
- subretinal (type2) CNV forms a subretinal Halo 
- Serous Retinal elevation, Fovealthickening, CMO, Hard 
exudates 
FA  
I. Classic CNV  Lacy Pattern  Extra Foveal 
Juxta Foveal 
Sub Foveal 
II. Occult CNV 
III. Fibrovascular PED (CNV + PED )  Hot Spot 
Course Prognosis is poor 
Complications: Hge PED, VT Hge, SR Scarring, Massive exudation 
TREATMENT 
I. PhotoDynamic Threapy  VERTEPORFIN 
Defnitive Indications  SF Classic CNV 
Probable Indications  Small, Pure occult lesions 
Possible Indications   Large occult lesions 
Contra Indications  PED 
Technique VPF 6mg/kg – 10 min 
Laser is applied to CNV – 83 Sec 
II. Anti – Arteriogenic Therapy 
- Intravitreal steroids 
- Anti – VEGF 
a. Avastin 
b. Lucentis 
c. Macugen 
III. Surgery - Submacular Surgery 
- Macular Translocation 
 
 
 
 
 
 
 
II. ANGIOGENESIS 
Angiogenesis is a physiological process involving the growth of new blood 
vessels from pre existing vessels. Though there has been some debate over this, 
vasculogenesis is the term used for spontaneous blood-vessel formation, and 
intussusception is the term for new blood vessel formation by splitting off existing 
ones. 
Types 
Sprouting angiogenesis 
Sprouting angiogenesis was the first identified form of angiogenesis. It occurs in 
several well characterized stages. First, biological signals known as angiogenic 
growth factors activate receptors present on endothelial cells present in pre-
existing veins. Second, the activated endothelial cells begin to release enzymes 
called proteases that degrade the basement membrane in order to allow 
endothelial cells to escape from the original (parent) vessel walls. The endothelial 
cells then proliferate into the surrounding matrix and form solid sprouts 
connecting neighboring vessels. As sprouts extend toward the source of the 
angiogenic stimulus, endothelial cells migrate in tandem, using adhesion 
molecules, the equivalent of cellular grappling hooks, called integrins. These 
sprouts then form loops to become a full-fledged vessel lumen as cells migrate to 
the site of angiogenesis. Sprouting occurs at a rate of several millimeters per day, 
and enables new vessels to grow across gaps in the vasculature. It is markedly 
different from splitting angiogenesis, however, because it forms entirely new 
vessels as opposed to splitting existing vessels. 
Intussusceptive angiogenesis 
Intussusception, also known as splitting angiogenesis, was first observed in 
neonatal rats. In this type of vessel formation, the capillary wall extends into the 
lumen to split a single vessel in two. There are four phases of intussusceptive 
angiogenesis. First, the two opposing capillary walls establish a zone of contact. 
Second, the endothelial cell junctions are reorganized and the vessel bilayer is 
perforated to allow growth factors and cells to penetrate into the lumen. Third, a 
core is formed between the two new vessels at the zone of contact that is filled 
with pericytes and myofibroblasts. These cells begin laying collagen fibers into 
the core to provide an extracellular matrix for growth of the vessel lumen. Finally, 
the core is fleshed out with no alterations to the basic structure. Intussusception is 
important because it is a reorganization of existing cells. It allows a vast increase 
in the number of capillaries without a corresponding increase in the number of 
endothelial cells. This is especially important in embryonic development as there 
are not enough resources to create a rich microvasculature with new cells every 
time a new vessel develops. 
 
Modem terminology of angiogenesis 
Besides the differentiation between "Sprouting angiogenesis" and 
"Intussusceptive angiogenesis" there exists the today more common 
differentiation between the following types of angiogenesis. 
Vasculogenesis - Formation of vascular structures from circulating or tissue-
resident endothelial stem cells (angioblasts), which proliferate into de novo 
endothelial cells. This form particularly relates to the embryonal development of 
the vascular system. 
Angiogenesis - Formation of thin - walled endothelium-lined structures 
with/without muscular smooth muscle wall and pericytes (fibrocytes). This 
formation plays an important role during adult life span, also as "repair 
mechanism" of damaged tissues. 
Arteriogenesis - formation of medium - sized blood vessels possessing tunica 
media plus adventitia 
Because it turned out even this differentiation is not a sharp one, today quite often 
the term "Angiogenesis" is used summarizing all different types and 
modifications of arterial vessel growth. 
 
 
 
 
 
 
 
 
III ANGIOGENESIS PROTEINS 
Stimulator Mechanism 
FGF Promotes proliferation & differentiation of 
endothelial cells , smooth muscle cells and 
fibroblasts  
VEGF Affects permeability 
VEGFR and NRP-1 Integrate survival signals 
Angl and Tie2 Stabilize vessels  
PDGF(BB-Homodimer) and PDGFR Recruit smooth muscle cells 
TGF-,endoglin and TGF – receptors  extracellular matrix production 
MCP-1  
Integrins v3, v5(?[9] ) and 51 Bind matrix macromolecules and proeinases 
VE-Catherin andCD31 Endothelial junctional molecules 
Ephrin Determine formation of arteries vein 
Plasminogen activators Remodels extra cellular matrix release and 
activates growth Factors  
Plasminogen activator inhibitor-1 Stabilize nearby vessels 
NOS and COX-2  
AC133 Regulate angioblast differentiation 
1d1 / 1d3 Regulates endothelial transdifferentiation 
 
 
 
FGF (Fibroblast Growth Factor) 
Further information: Fibroblast Growth Factor 
The fibroblast growth factor (FGF) family with its prototype members FGF - 1 
(acidic FGF) and FGF - 2 (basic FGF) consists to date of at least 22 known 
members. Most are 16-18 kDa single chain peptides and display high affinity to 
heparin and heparin sulfate. In general, FGFs stimulate a variety of cellular, 
functions by binding to cell surface FGF - receptors in the presence of heparin 
proteoglycans. The FGF - receptor family is composed of seven members and all 
the receptor proteins are single chain receptor tyrosine kinases that become 
activated through autophosphorylation induced by a mechanism of FGF mediated 
receptor dimerization. Receptor activation gives rise to a signal transduction 
cascade that leads to gene activation and diverse biological responses, including 
cell differentiation, proliferation, and matrix, dissolution - thus initiating a process 
of mitogenic activity critical for the growth of endothelial cells, fibroblasts, and 
smooth muscle cells. FGF -1, unique among all 22 members of the FGF family, 
can bind to all seven FGF - receptor subtypes, making it the broadest acting 
member of the FGF family, and a potent mitogen for the diverse cell types needed 
to mount an angiogenic response in damaged (hypoxic) tissues, where up 
regulation of FGF - receptors occurs. FGF- I stimulates the proliferation and 
differentiation of all cell types necessary for building an arterial vessel, including 
endothelial cells and smooth muscle cells, this fact distinguishes FGF -1 from 
other proangiogenic growth factors, such as vascular endothelial growth factor 
(VEGF) which primarily derives the formation of new capillaries. 
Until now (2007), three human clinical trials have been successfully completed 
with FGF -I in which the angiogenic protein was injected directly into the 
damaged heart muscle. Also, one additional human FGF-I trial has been 
completed to promote wound healing in diabetics with chronic wounds. 
 
Besides FGF-I, one of the most important functions of also fibroblast growth 
factor-2 (FGF-2 or bFGF) is the promotion of endothelial cell proliferation and 
the physical organization of endothelial cells into tube-like structures, thus 
promoting angiogenesis. FGF-2 is a more potent angiogenic factor than VEGF or 
PDGF (platelet-derived growth factor), however, less potent than FGF-l. As well 
as stimulating blood vessel growth, a FGF (FGF-I) and Bfgf (FGF-2) are 
important players in wound healing. They stimulate the proliferation of fibroblasts 
and endothelial cells that give rise to angiogenesis and developing granulation 
tissue, both increase blood supply and fill up a wound space/cavity early in the 
wound healing process. 
 
VEGF (Vascular Endothelial Growth Factor) 
VEGF (Vascular Endothelial Growth Factor) has been demonstrated to be a major 
contributor to angiogenesis, increasing the number of capillaries in a given 
network. Initial in Vitro studies demonstrated that bovine capillary endothelial 
cells will proliferate and show signs of tube structures upon stimulation by VEGF 
and b FGF, although the result were more pronounced with VEGF. Upregulation 
of VEGF is a major component of the physiological response to exercise and its 
role in angiogenesis is suspected to be a possible treatment in vascular injuries. In 
vitro studies clearly demonstrate that VEGF is a potent stimulator of angiogenesis 
because in the presence of this growth factor plated endothelial cells will 
proliferate and migrate, eventually forming tube structures resembling capillaries. 
VEGF causes a massive signaling cascade in endothelial cells. Binding to VEGF 
receptor -2 (VEGFR-2) starts a tyrosine kinase signaling cascade that stimulates 
the production of factors that variously stimulate vessel permeability (eNoS, 
producing NO), proliferation/survival (Bfgf), migration (ICAMSNCAMs/MMPs) 
and finally differentiation into mature blood vessels. Mechanically, VEGF is 
upregulated with muscle contractions as a result of increased blood flow to 
affected areas. The increased flow also causes a large increase in the m RNA 
production of VEGF receptors 1 and 2. The increase in receptor production means 
that muscle contractions could cause upregulation of the signaling cascade 
relating to angiogenesis. As part of the angiogenic signaling cascade, NO is 
widely considered to be a major contributor to the angiogenic response because 
inhibition of NO significantly reduces the effects of angiogenic growth factors. 
However, inhibition of NO during exercise does not inhibit angiogenesis 
indicating that there are other factors involved in the angiogenic response. 
 
Angiopoietins 
The angiopoietins, Angl and Ang2, are required for the formation of mature blood 
vessels, as demonstrated by mouse knock out studies. Ang 1 and Ang 2 are 
protein growth factors which act by binding their receptors. Tie-l and Tie-2, while 
this is somewhat controversial, it seems that cell signals are transmitted mostly by 
Tie-2, though some papers show physiologic signaling via Tie-l as well. These 
receptors are tyrosine kinases. Thus, they can initiate cell signaling when ligand 
binding causes a dimerization that initiates phosphorlation on key tyrosines. 
 
MATRIX METALLO PROTEINASE  
Another major contributor to angiogenesis is matrix metallo proteinase (MMP). 
MMPs help degrade the proteins that keep the vessel walls solid. This proteolysis 
allows the endothelial cells to escape into the interstitial matrix as seen in 
sprouting angiogenesis. Inhibition of MMPs prevents the formation of new 
capillaries. These enzymes are highly regulated during the vessel formation 
process because destruction of the extracellular matrix would decrease the 
integrity of the microvasculature. 
 
IV ANGIOGENESIS PATHWAY 
Vascular endothelial growth factor (VEGF) plays a key role in physiological 
blood vessel formation. Hypoxia is a potent inducer of VEGF in vitro, The 
increase in secreted biologically active VEGF protein from cells exposed to 
hypoxia is partly because of an increased transcription rate, mediated by binding 
of hypoxia-inducible factor-l (HIFl) to a hypoxia responsive element in the 5’-
flanking region of the VEGF gene, bHLH-PAS transcription factor that interacts 
with the Ah receptor nuclear translocator (Arnt), and its predicted amino acid 
sequence exhibits significant similarity to the hypoxia-inducible factor l alpha 
(HIFla) product, HLF mRNA expression is closely correlated with that of VEGF 
mRNA.. The high expression level of HLF mRNA in the 02 delivery system of 
developing embryos and adult organs suggests that in a normoxic state, HLF 
regulates gene expression of VEGF, various glycolytic enzymes, and others 
driven by the HRE sequence, and may be involved in development of blood 
vessels and the tubular system of lung, VEGF expression is dramatically induced 
by hypoxia due in large part to an increase in the stability of its mRNA, HuR 
binds with high affinity and specificity to the VRS element that regulates VEGF 
mRNA stability by hypoxia. The secreted VEGF is a major angiogenic factor that 
regulates multiple endothelial cell functions, including mitogenesis. Cellular and 
circulating levels of VEGF are elevated in hematologic malignancies and are 
adversely associated with prognosis. Angiogenesis is a very complex, tightly 
regulated, multistep process, the targeting of which may well prove useful in the 
creation of novel therapeutic agents. Current approaches being investigated 
include the inhibition of angiogenesis stimulants (e.g., VEGF), or their receptors, 
blockade of endothelial cell activation, inhibition of matrix metallo proteinases. 
 
 
 
 
 
 
 
 
V. AVASTIN IN DETAIL 
Bevacizumab is an immunoglobulin G (IgG) composed of two identical light 
chains, consisting of 214 amino acid residues and two 453 residue heavy chains 
containing an N-linked oligosaccharide and has a molecular weight of 
approximately 149,000 daltons. 
 
DESCRIPTION 
AVASTIN is a clear to slightly opalescent, colourless to pale brown sterile 
solution for intravenous (IV) infusion. AVASTIN is available in 100 mg and 400 
mg single dose vials containing 4 mL and 16 mL, respectively of bevacizumab 
(25 mg/mL). AVASTIN also contains a trehalose dihydrate, monobasic 
monohydrate sodium phosphate, dibasic sodium phosphate, polysorbate 20 and 
water for injections. 
 
PHARMACOLOGY 
Mechanism of Action 
AVASTIN is an antineoplastic agent containing the active ingredient, 
bevacizumab. Bevacizumab is a recombinant humanised monoclonal antibody 
that selectively binds to and neutralises the biologic activity of human vascular 
endothelial growth factor (VEGF). Bevacizumab contains human framework 
regions with antigen binding regions of a humanised murine antibody that binds 
to VEGF. Bevacizumab is produced by recombinant DNA technology in a 
Chinese hamster ovary mammalian cell expression system in a nutrient medium 
containing the antibiotic gentamicin and is purified by a process that includes 
specific viral inactivation and removal steps. Gentamicin is detectable in the final 
product at <= 0.35 ppm. 
AVASTIN inhibits the binding of VEGF to its receptors, Flt-l and KDR, on the 
surface of endothelial cells. Neutralising the biologic activity of VEGF reduces 
the vascularisation of tumours, thereby inhibiting tumour growth. Administration 
of bevacizumab or its parental murine antibody to xenotransplant models of 
cancer in nude mice resulted in extensive antitumour activity in human cancers, 
including colon, breast, pancreas and prostate. Metastatic disease progression was 
inhibited and microvascular permeability was reduced. 
 
PHARMACOKINETICS 
The pharmacokinetics of bevacizumab were characterised in patients with various 
types of solid tumours. The doses tested were 0.1-10 mg/kg weekly in phase I; 3-
20 mg/kg every two weeks (q2w) or every three weeks (q3w) in phase II; 5 mg/kg 
(q2w) or 15 mg/kg q3w in phase III. In all clinical trials, bevacizumab was 
administered as an IV infusion. 
As observed with other antibodies, the pharmacokinetics of bevacizumab are well 
described by a two-compartment model. Overall, in all clinical trials, 
bevacizumab disposition was characterised by a low clearance, a limited volume 
of the central compartment (VC), and a long elimination half-life. This enables 
target therapeutic bevacizumab plasma levels to be maintained with a range of 
administration schedules (such as one administration every 2 or 3 weeks). 
In the population pharmacokinetics analysis there was no significant difference in 
the pharmacokinetics of bevacizumab in relation to age (no correlation between 
bevacizumab clearance and subject age [the median age was 59 years with 5th  
and 95th percentiles of 37 and 76 years]). 
Low albumin and high alkaline phosphatase levels are generally indicative of 
disease severity and tumour burden. Bevacizumab clearance was approximately 
20% higher either in subjects with low levels of serum albumin or in subjects with 
elevated alkaline phosphatase levels when compared with the typical subject with 
median values of albumin and/or alkaline phosphatase. 
 
Distribution 
The typical value for Vc was 2.66 L and 3.25 L for female and male subjects, 
respectively, which is in the range that has been described for IgGs and other 
monoclonal antibodies. After correcting for body weight, male subjects had a 
larger Vc (+22%) than females. 
Metabolism 
Assessment of bevacizumab metabolism in rabbits following a single IV dose of 
1251- bevacizumab suggested that its metabolic profile was similar to that 
expected for a native IgG molecule which does not bind VEGF. 
 
Elimination 
The pharmacokinetics of bevacizumab are linear at doses ranging from 1.5 to 10 
mg/kg/wk. 
The value for clearance is, on average, equal to 0.207 and 0.262 L/day for female 
and male subjects, respectively. After correcting for body weight, male subjects 
had a higher bevacizumab clearance (+26%) than females. According to the bi-
compartmental model, the initial half-life () is 1.4 days for both sexes, and the 
terminal () half-life estimate is 20 days for a typical female subject and 19 days 
for a typical male. 
 
Pharmacokinetics in Special Populations 
The population pharmacokinetics of bevacizumab were analysed to evaluate the 
effects of demographic characteristics. The results showed no significant 
difference in the pharmacokinetics of bevacizumab in relation to age. 
 
Children and Adolescents: No formal studies have been conducted to examine the 
pharmacokinetics of bevacizumab in children and adolescent patients. 
 
Renal impairment: No formal studies have been conducted to examine the 
pharmacokinetics of bevacizumab in subjects with renal impairment. 
 
Hepatic impairment: No formal studies have been conducted to examine the 
pharmacokinetics of bevacizumab in subjects with hepatic impairment. 
 
 
 
VI. AVASTIN IN VARIOUS DISEASES 
PROLIFERATIVE DIABETIC RETINOPATHY 
Haritoglou C and et al., 2006 evaluated the efficacy of bevacizumab for the 
treatment of diabetic macular edema in 51 consecutive patients (26 females and 
25 males; mean age, 64 years) with diffuse diabetic macular edema. Inclusion 
criteria were determined independently of the size of edema, retinal thickness, 
visual acuity, age, metabolic control, type of diabetes, or previous treatments 
beyond a 6-month period.  All patients had undergone previous treatments, such 
as focal laser therapy (35%), full-scatter panretinallaser therapy (37%), 
vitrectomy (12%), and intravitreal injection of triamcinolone (33%). Changes in 
ETDRS letters were not significant throughout follow-up. Mean retinal thickness 
+/- SD decreased to 425 +/- 180 micro m at 2 weeks (P = 0.002), 416 +/- 180 
micro m at 6 weeks (P = 0.001), and 377 +/117 micro m at 12 weeks (P = 0.001). 
Changes of retinal thickness and visual acuity correlated weakly (r = -0.480 and P 
= 0.03 at 6 weeks; r = -0.462 and P = 0.07 at 12 weeks). The increase of visual 
acuity after 6 weeks as measured by ETDRS charts could be predicted best by 
baseline visual acuity. No other factors investigated, such as age, thickness by 
optical coherence tomography, or previous treatments, were predictive for the 
increase in visual acuity.  
Hence diffuse diabetic macular edema not responding to previous treatments such 
as photocoagulation, intravitreal injection of triamcinolone, or vitrectomy, 
improvement of visual acuity and decrease of retinal thickness could be observed 
after intravitreal injection of bevacizumab. Although our follow-up period was 
too short to provide specific treatment recommendations, the short-term results 
encourage further prospective studies with different treatment groups and longer 
follow-up. 
 
CENTRAL RETINAL VEIN OCCLUSION  
Costa RA and et al., 2007 evaluated the safety, visual acuity changes, and 
morphologic effects associated with intravitreal bevacizumab injections for the 
management of macular edema due to ischemic central retinal vein occlusion 
(CRVO). In this prospective, open-label study, 7 consecutive patients (7 eyes) 
with macular edema associated with ischemic central or hemicentral RVO were 
treated with intravitreal injections of 2.0 mg (0.08 mL) of bevacizumab at 12-
week intervals.  
The median age of the 7 patients was 65 years (range, 58-74 years), and the 
median duration of symptoms before injection was 7 months (range, 2.5-16 
months). At baseline, mean BCVA was 1.21 (Snellen equivalent, approximately 
20/320) in the affected eye. Mean baseline CMT and TMV were 730.1 microm 
and 17.1 mm (3), respectively. Fluorescein leakage was observed in the macula 
and affected retinal quadrants in all seven eyes. Six patients completed the 25-
week follow-up examination with reinjections performed at weeks 12 and 24. The 
most common adverse events were conjunctival hyperemia and subconjunctival 
hemorrhage at the injection site. At the last follow-up, mean BCVA in the 
affected eye was 0.68 (Snellen equivalent, 20/100(+1). No patient had a decrease 
in BCVA. Mean CMT and TMV at the 25-week follow-up were 260.3 micron and 
9.0 mm(3), respectively; fluorescein leakage within the macula and affected 
retinal quadrants as compared with baseline was markedly reduced in all patients. 
Coupled with fluorescein angiographic findings, OCT data suggest a trend of 
macular edema recurrence between 6 weeks and 12 weeks after injection.  
Hence Intravitreal bevacizumab injections of 2.0 mg at 12-week intervals were 
well tolerated and were associated with short-term BCVA stabilization or 
improvement and favourable macular changes in all patients with ischemic RVO 
and associated macular edema. 
 
AGE-RELATED MACULAR DEGENERATION 
Goff MJ and et al., 2007 reported the optical coherence tomography (OCT) 
findings and visual results in a series of patients treated with intravitreal 
bevacizumab for choroidal neovascularization (CNV) associated with age-related 
macular degeneration (ARMD), and to determine if a difference in treatment 
effect exists between previously treated and treatment patients. A retrospective 
review of all patients treated with intravitreal bevacizumab for CNV from ARMD 
with visual acuity greater than or equal to 20/320 between September 2005 and 
February 2006 was performed. Fifty-four eyes of 51 patients treated with 
intravitreal bevacizumab for CNV from ARMD were identified. A total of 178 
injections were performed. Mean number of days of follow-up was 138 with 91 % 
of patients having at least 90 days of follow-up. Seventy percent of patients had 
undergone previous treatment for CNV. The mean number of intravitreal 
bevacizumab injections per eye was 3.3. Combined treatment with photodynamic 
therapy was provided in 20% of cases at the initial intravitreal injection. OCT data 
for all patients revealed an initial mean thickness of 362 mum, which was 
decreased at 1 week to 278 micron (P = 0.001), 235 micron at 1 month 
(P<0.0001), 238 micron at 3 months (P = 0.0004), and 244 micron for the end of 
follow up (P < 0.0001). Cystic retinal edema, subretinal fluid, and pigment 
epithelial detachment resolved in the majority of cases, but pigment epithelial 
detachment frequently took longer to resolve. Initial mean visual acuity was 
20/125 (logMAR 0.8), and final mean visual acuity was 20/100 (logMAR 0.7) (P 
= 0.03). There was no difference in OCT or visual acuity outcomes (P = 0.62 and 
P = 0.28, respectively) between previously treated and treatment naIve patients. 
There was no difference in OCT or visual acuity outcomes (P = 0.67 and P = 0.21, 
respectively) between patients who received combination therapy and those who 
received monotherapy with intravitreal bevacizumab. No systemic or ocular 
adverse events were recorded. Hence Intravitreal bevacizumab for CNV from 
ARMD results in a rapid decrease in OCT-measured retinal thickness in a 
majority of cases. Visual acuity also improved in this series, suggesting a 
potential corresponding visual benefit. This series suggests that previously treated 
and treatment naive patients have similar outcomes. 
 
 
 
 
 
VII. Complication of Intraviteral Injection of Avastin 
Complication of Intraviteral Injection of Avastin 
General Complications 
• Cataract 
• Glaucoma 
• Vitreous Heemorrhage 
• Retinal detachment 
• Endophthalmitis 
Specific Complications 
• Retinal pigment epithelial rip 
• Submacular haemorrhage 
• Progression of tractional retinal detachment 
• Visual hallucinations 
• Metrorrhagia 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Patients and Methods 
 
PATIENTS AND METHODS 
This prospective, interventional study was done at Retina Clinic, Institute of 
Ophthalmology, Joseph Eye Hospital, Tiruchirapalli from June 2007 to July 2008. 
Inclusion Criteria 
1 Patients with Proliferative Diabetic Retinopathy 
2 Patients with retinal vein occlusion and neovascularization 
3 Patients with wet Age related Macular Degeneration   
Exclusion Criteria 
1. Presence of other retinal pathaology affecting Visual Acuity 
2. Presence of Significant cataract 
Complete medical and ocular history was taken in the baseline visit. All patients 
underwent a complete ophthalmic examinations which include: 
1 Best corrected distant and near vision 
2 Intraocular pressure 
3 Slit lamp examination 
4 Fundus examination 
5 Fundus photography 
6 Fundus Fluorescein Angiography 
7 Macular thickness with OCT 
 
 
 
 
Procedure 
All patients were informed of the procedure, the possible complications and 
informed consent was obtained. The institute ethics committee approved the 
study. 
 
Peribulbar anaethesia was given. 2 drops of 5% Povidone – Iodine were instilled 
in the eye followed by through cleaning of the eye lashes and application of lid 
speculum. 
 
0.1 ml (4 mg) of Bevacizumab (Roche India Ltd, Mumbai, India) was drawn in a 
2 cc syringe and fitted with  26 g (1/2 inch) needle. The injection site was usually 
the inferotemporal quadrant to avoid drug deposition in front of the visual axis. 
The site of injection was 3.5 mm and 4 mm from limbus in pseudophakic and 
phakic eyes respectively. The needle was introduced downwards and backwards 
with the bevel of the needle facing anteriorly. This was done to avoid contact of 
the drug with macula. After injection, the needle was removed simultaneously 
with the application of a cotton tipped applicator over its entry site to prevent 
regurgitation of the inject material. One drop of topical antibiotic solution was 
administered and the eye was patched. 
 
The patient was made to sit up immediately after injection and continue 
maintaining erect posture for atleast 6 hours. All patients were started on capsule 
acetazolamide (sustained release) 500 mg two times a day for 3 days, 0.5% 
timolol maleate eye drops twice daily for 1 month and antibiotic eye drops 6 times 
a day for 1 week. 
  
Follow up examination was done at 3 days, 2 weeks, 1 month and then at monthly 
intervals for 6 months. 
On follow up the examinations done were: 
1 Best corrected distant and near vision 
2 Intraocular pressure 
3 Slit lamp examination 
4 Fundus examination 
5 Fundus photography 
6 Macular thickness with OCT 
7 Fundus Fluorescein Angiography 
The Main outcome measures are: 
 Visual Acuity / regression of new vessels 
 
 
 
 
 
 
 
 
 Bevacizumab preparation 
 
 
 
Caliper Showing 4 mm from the Limbus 
 
 
BEVACIZUMAB INJECTED INTO THE EYE 
 
 
 
 
 
 
  
 
 
 
 
Results 
 
RESULTS 
50 Eyes of 50 patients received an intravitreal injection of 4 mg (0.1 ml) of 
Bevacizumab (Avastin) during the study period (June 2007 to July 2008). Induded 
Diabetic Retinopathy, Branch Retinal Vein Occlusion, Central Retinal Vein 
Occlusion, Age related Macular Degeneration.  
AGE DISTRIBUTION 
Table – 1 
Distribution of Patients by their Age  
Age Group (Years) No. of Patients Percentage (%) 
30-40 2 4 
41-50 12 24 
51-60 23 46 
61-70 10 20 
71-80 3 6 
Total 50 100 
 Source: Master Chart 
 
 
  
 
 
 
 
As seen in the age distribution 4% of patients were in the age group of 30-40 
years, 24% patients were in the age group of 41-50 years, 46% of patients were in 
the age group of 51-60 years, 20% of patients were in the age group of 61-70 
years and 6% of patients were in the age group of 71-80.  
Majority of patients (46%) belonged to the Age group of 51 – 60. The youngest 
patient was 39 years of age and the eldest 75 years.  
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GENDER DISTRIBUTION 
Table – 2 
Distribution of Patients by their Gender 
Gender No. of Patients Percentage (%) 
Male 21 42 
Female 29 58 
Total 50 100 
  Source: Master Chart 
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As seen in the Gender distribution 42 %( 21 out of 50) of patients are male and 
remaining 58% (29 out of 50) of patients are female. 
  
 
 
 
 
 
 
 
 
 
DISEASE DISTRIBUTION 
Table – 3 
Distribution of Patients by their Disease  
Disease No. of Patients Percentage (%) 
PDR 33 66 
BRVO 3 6 
CRVO 3 6 
ARMD 11 22 
  Source: Master Chart 
 
As seen in the Disease Distribution by patient wise was inferred that 66% of 
patients were suffered from PDR (Diabetic Retinopathy), 6% of patients were 
suffered from BRVO (Retinal Vein Occlusions), 6% of patients were suffered 
from CRVO (Central Retinal Vein Occlusions) and 22% of patients were suffered 
from ARMD (Age related Macular Degeneration). 
 
 
 
Distribution of Patients by their Disease 
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Pre Injection Best Visual Acuity  
Table – 4 
Distribution of Patients by Pre Injection Best Visual Acuity (BCVA)  
 
No. of Patients Visual Acuity  
(in Decimal) PDR BRVO CRVO ARMD 
0.02 9 0 0 3 
0.03 3 0 1 1 
0.05 1 0 0 0 
0.07 1 0 0 1 
0.08 6 1 0 3 
0.10 7 0 2 3 
0.17 1 0 0 0 
0.25 2 0 0 0 
0.33 1 0 0 0 
0.50 1 1 0 0 
0.67 1 0 0 0 
1.00 0 1 0 0 
 Source: Master Chart 
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As seen in the Pre injection Best visual Acuity distribution by patient wise was 
inferred that 12 No. of patients (PDR-9, BRVO -0, CRVO – 0, ARMD – 3) were 
affected by visual acuity at the level of 1/60(0.02 in decimal), 5 No. of patients 
(PDR-3, BRVO -0, CRVO – 1, ARMD – 1) were affected by visual acuity at the 
level of 2/60(0.03 in decimal), 1 No. of patient (PDR-1, BRVO -0, CRVO – 0, 
ARMD – 0) were affected by visual acuity at the level of 3/60(0.05 in decimal),  2 
No. of patients(PDR-1, BRVO -0, CRVO – 0, ARMD – 1) were affected by 
visual acuity at the level of 4/60(0.07 in decimal). 
 
10 No. of patients (PDR-6, BRVO -1, CRVO – 0, ARMD -3) were affected by 
visual acuity at the level of 5/60(0.08 in decimal), 12 No. of patients (PDR-7, 
BRVO -0,CRVO – 2, ARMD - 3) were affected by visual acuity at the level of 
6/60(0.10 in decimal), 1 No. of patient (PDR-1, BRVO -0, CRVO – 0, ARMD – 
0) were affected by visual acuity at the level of 6/36(0.17 in decimal). 
 
2 No. of patients (PDR-2, BRVO -0, CRVO – 0, ARMD - 0) were affected by 
visual acuity at the level of 6/24(0.25 in decimal), 1 No. of patient (PDR-1, 
BRVO -0, CRVO – 0, ARMD – 1) were affected by visual acuity at the level of 
6/18(0.33 in decimal)  2 No. of patients (PDR-1, BRVO -1, CRVO – 0, ARMD – 
0) were affected by visual acuity at the level of 6/12(0.50 in decimal), 1 No. of 
patient (PDR-0, BRVO -1, CRVO – 0, ARMD – 0) were affected by visual acuity 
at the level of 6/9(0.67 in decimal) and 1 No. of patients (PDR-1, BRVO -
0,CRVO – 0, ARMD – 0) were affected by visual acuity at the level of 6/6(1.00 in 
decimal). 
 
 
 
 
 
 
 
Pre Injection Visual Acuity Mean Value  
Table -5 
Mean Pre Injection Visual Acuity (BCVA)  
Disease 
Visual Acuity Mean Value 
 (in Decimal) 
PDR 0.11 
BRVO 0.53 
CRVO 0.08 
ARMD 0.06 
   Source: Master Chart 
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As seen in the Pre injection Best visual Acuity distribution by disease wise was 
inferred that mean value for Pre injection Visual Acuity was 0.11 (in decimal) for 
PDR,  that mean value for Pre injection Visual Acuity was 0.53 (in decimal) for 
BRVO,  that mean value for Pre injection Visual Acuity was 0.08 (in decimal) for 
CRVO and that mean value for Pre injection Visual Acuity was 0.06 (in decimal) 
for ARMD. 
 
Post Injection Visual Acuity Mean Value 
Table – 6 
Mean Post Injection Visual Acuity  
Disease 
Visual Acuity Mean Value  
(in Decimal) 
PDR 0.28 
BRVO 0.56 
CRVO 0.06 
ARMD 0.17 
Source: Master Chart 
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As seen in the Post injection Best visual Acuity distribution by patient wise was 
inferred that the mean value of post injection of Best Visual Acuity was 0.28 
(PDR), 0.56(BRVO), 0.06 (CRVO) and 0.17 (ARMD). After the 2 weeks interval 
period all the mean value indicated that the vision was improved. The highest 
mean value of Best Visual Acuity Right eye was 0.56 decimal (CRVO decimal).  
 
 
 
Post Injection improvement Visual Status  
Table – 7 
Post injection Visual Status, Disease Wise 
Disease Improvement in Eyes Remained Same 
PDR 27 6 
BRVO 2 1 
CRVO 2 1 
ARMD 9 2 
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As seen in the Post injection Best visual Acuity improvement distribution by 
disease wise was inferred that 27 No. of eyes in PDR, 2  No. of eyes in BRVO, 2 
No. of eyes in CRVO and 9 No. of eyes in ARMD had improved by post injection 
against visual status, Disease. 6 No. of eyes in PDR, 1 No. of eye in BRVO, 1 No. 
of eye in CRVO and 2 No. of patients were in same condition. 
 
 
 
Distribution of Post Injection improvement Visual Status 
Table – 8 
Post Injection Visual Status, Patient Wise 
Visual Status 
Improvement (No. of 
Patients) Percentage (%) 
Improvement 40 80 
Remained Same 10 20 
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As seen in the Post injection Best visual Acuity improvement distribution by 
patient wise was inferred that 80% of Patients Visual Acuity status was improved 
after the post injection period and 20% of patients were remained in same 
position.  
 
 
 
 
 
 
 
 
Pre and Post Injection Periodical BCVA  
Table - 9 
Change in Best Corrected Visual Acuity (BCVA) 
Period 
Mean BCVA 
(in  Decimal) 
P value ( T Test) 
Pre injection 0.12  
Post injection  0.26 0.001 
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As seen in the Post injection Change Best visual Acuity was inferred that there is 
statistically significant relationship between periodical injection and 
improvement. In the subsequent visits, the improved vision was statically 
significant (p=0.001). 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pre Injection (PDR) Diabetic  Post Injection (PDR) Diabetic 
Retinopathy       Retinopathy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pre Injection (BRVO) Retinal  Post Injection (BRVO) Retinal 
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OCT 
  
 
 
 
 
Discussion 
 
DISCUSSION 
PROLIFERATIVE DIABETIC RETINOPATHY 
Haritoglou C and et al., 2006 evaluated the efficacy of bevacizumab for the 
treatment of diabetic macular edema in 51 consecutive patients (26 females and 
25 males; mean age, 64 years) with diffuse diabetic macular edema. Inclusion 
criteria were determined independently of the size of edema, retinal thickness, 
visual acuity, age, metabolic control, type of diabetes, or previous treatments 
beyond a 6-month period.  All patients had undergone previous treatments, such 
as focal laser therapy (35%), full-scatter panretinallaser therapy (37%), 
vitrectomy (12%), and intravitreal injection of triamcinolone (33%). . Changes in 
ETDRS letters were not significant throughout follow-up. Mean retinal thickness 
+/- SD decreased to 425 +/- 180 micro m at 2 weeks (P = 0.002), 416 +/- 180 
micro m at 6 weeks (P = 0.001), and 377 +/117 micro m at 12 weeks (P = 0.001). 
Changes of retinal thickness and visual acuity correlated weakly (r = -0.480 and P 
= 0.03 at 6 weeks; r = -0.462 and P = 0.07 at 12 weeks). The increase of visual 
acuity after 6 weeks as measured by ETDRS charts could be predicted best by 
baseline visual acuity. No other factors investigated, such as age, thickness by 
optical coherence tomography, or previous treatments, were predictive for the 
increase in visual acuity.  
Hence diffuse diabetic macular edema not responding to previous treatments such 
as photocoagulation, intravitreal injection of triamcinolone, or vitrectomy, 
improvement of visual acuity and decrease of retinal thickness could be observed 
after intravitreal injection of bevacizumab. Although our follow-up period was 
too short to provide specific treatment recommendations, the short-term results 
encourage further prospective studies with different treatment groups and longer 
follow-up. 
In Present study showed, Diabetic Retinopathy in 50 eyes Pre injection Visual 
Acuity mean value was 0.11 (in decimal). The follow up in this study was at 3 
days, 2 weeks, and 1 month at monthly interval for 6 months. The mean value in 
PDR is statically significant in almost all visits and post injection visual acuity 
mean value was 0.27 (in decimal). The present study showed an improvement in 
visual acuity in 27 eyes. In 6 eyes visual acuity remained the same position after 
the post injection. 
 
CENTRAL RETINAL VEIN OCCLUSION  
Costa RA and et al., 2007 evaluated the safety, visual acuity changes, and 
morphologic effects associated with intravitreal bevacizumab injections for the 
management of macular edema due to ischemic central retinal vein occlusion 
(CRVO). In this prospective, open-label study, 7 consecutive patients (7 eyes) 
with macular edema associated with ischemic central or hemicentral RVO were 
treated with intravitreal injections of 2.0 mg (0.08 mL) of bevacizumab at 12-
week intervals.  
The median age of the 7 patients was 65 years (range, 58-74 years), and the 
median duration of symptoms before injection was 7 months (range, 2.5-16 
months). At baseline, mean BCVA was 1.21 (Snellen equivalent, approximately 
20/320) in the affected eye. Mean baseline CMT and TMV were 730.1 microm 
and 17.1 mm(3), respectively. Fluorescein leakage was observed in the macula 
and affected retinal quadrants in all seven eyes. Six patients completed the 25-
week follow-up examination with reinjections performed at weeks 12 and 24. The 
most common adverse events were conjunctival hyperemia and subconjunctival 
hemorrhage at the injection site. At the last follow-up, mean BCVA in the 
affected eye was 0.68 (Snellen equivalent, 20/100(+1). No patient had a decrease 
in BCVA. Mean CMT and TMV at the 25-week follow-up were 260.3 micron and 
9.0 mm(3), respectively; fluorescein leakage within the macula and affected 
retinal quadrants as compared with baseline was markedly reduced in all patients. 
Coupled with fluorescein angiographic findings, OCT data suggest a trend of 
macular edema recurrence between 6 weeks and 12 weeks after injection.  
Hence Intravitreal bevacizumab injections of 2.0 mg at 12-week intervals were 
well tolerated and were associated with short-term BCVA stabilization or 
improvement and favourable macular changes in all patients with ischemic RVO 
and associated macular edema. 
In Present study showed Central Retinal vein occlusions in 50 eyes Pre injection 
Visual Acuity in was 0.08 (in decimal). The follow up in this study was at 3 days, 
2 weeks, and 1 month at monthly interval for 6 months. The mean value in CRVO 
is statically significant in almost visits and post injection visual acuity mean value 
was 0.06 (in decimal). The present study showed an improvement in visual acuity 
in 2 eyes. In 1 Eye visual acuity remained the same position after the post 
injection. 
 
AGE-RELATED MACULAR DEGENERATION 
Goff MJ and et al., 2007 reported the optical coherence tomography (OCT) 
findings and visual results in a series of patients treated with intravitreal 
bevacizumab for choroidal neovascularization (CNV) associated with age-related 
macular degeneration (ARMD), and to determine if a difference in treatment 
effect exists between previously treated and treatment patients. A retrospective 
review of all patients treated with intravitreal bevacizumab for CNV from ARMD 
with visual acuity greater than or equal to 20/320 between September 2005 and 
February 2006 was performed. Fifty-four eyes of 51 patients treated with 
intravitreal bevacizumab for CNV from ARMD were identified. A total of 178 
injections were performed. Mean number of days of follow-up was 138 with 91 % 
of patients having at least 90 days of follow-up. Seventy percent of patients had 
undergone previous treatment for CNV. The mean number of intravitreal 
bevacizumab injections per eye was 3.3. Combined treatment with photodynamic 
therapy was provided in 20% of cases at the initial intravitreal injection. OCT data 
for all patients revealed an initial mean thickness of 362 mum, which was 
decreased at 1 week to 278 micron (P = 0.001), 235 micron at 1 month 
(P<0.0001), 238 micron at 3 months (P = 0.0004), and 244 micron for the end of 
follow up (P < 0.0001). Cystic retinal edema, subretinal fluid, and pigment 
epithelial detachment resolved in the majority of cases, but pigment epithelial 
detachment frequently took longer to resolve. Initial mean visual acuity was 
20/125 (logMAR 0.8), and final mean visual acuity was 20/100 (logMAR 0.7) (P 
= 0.03). There was no difference in OCT or visual acuity outcomes (P = 0.62 and 
P = 0.28, respectively) between previously treated and treatment naIve patients. 
There was no difference in OCT or visual acuity outcomes (P = 0.67 and P = 0.21, 
respectively) between patients who received combination therapy and those who 
received monotherapy with intravitreal bevacizumab. No systemic or ocular 
adverse events were recorded. Hence Intravitreal bevacizumab for CNV from 
ARMD results in a rapid decrease in OCT-measured retinal thickness in a 
majority of cases. Visual acuity also improved in this series, suggesting a 
potential corresponding visual benefit. This series suggests that previously treated 
and treatment naive patients have similar outcomes. 
 
In Present study showed Age Related macular degeneration in 50 eyes Pre 
injection Visual Acuity in was 0.06 (in decimal). The follow up in this study was 
at 3 days, 2 weeks, and 1 month at monthly interval for 6 months. The mean value 
in ARMD is statically significant in almost visits and post injection visual acuity 
mean value was 0.25 (in decimal). The present study showed an improvement in 
visual acuity in 9 eyes. In 2 eyes visual acuity remained the same position after 
the post injection. 
 
 
 
 
 
 
  
 
 
 
 
Summary 
 
SUMMARY 
The Study entitled “The role of Intravitreal Bevacizumab in the Management of 
Various Retinal Vascular Diseases” was conducted at Retina Clinic, Institute of 
Ophthalmology, Joseph Eye Hospital, Tiruchirapalli. A total of 50 eyes of 50 
patients were studied. 
Baseline ophthalmic examination included: 
 Best corrected visual acuity 
 IOP measurement 
 Slit lamp examination 
 Fundus examination (+90 D lens & Indirect Ophthalmoscopy) 
 Fundus photography 
 Macular thickness with OCT 
 Fundus Fluorescein Angiography 
Follow up was done at 3 days, 2 weeks, 1 month and then at monthly interval for 
six months. 
 
Observations 
 Maximum number of patients belongs to the age group of 51 – 60 years. 
 Out of 50 respondents 29 were female and 21were male. 
 50 patients have received injection in one of the eyes. 
 33 cases had diabetic retinopathy, 3 cases were branch retinal vein 
occlusion and 3 cases also central retinal vein occlusion. 11 cases were 
Age related Macular Degeneration 
  50 eyes received 4 mg (0.1 ml) of Bevacizumab (Avastin) 
 Vision improved in 40 eyes (80%) and 10 eyes (20%) were remained same 
 Post injection visual acuity improvement was statistically significant after 
1 month and in all the follow up visits thereafter. 
 There was statistically significant relationship between periodical injection 
and improvement in visual acuity. 
 PDR was seen in 33 patients. In 27 eyes were improved and 6 eyes were 
remained same. 
 BRVO was seen in 3 patients. In 2 eyes were improved and 1 eye was 
remained same. 
 CRVO was seen in 3 patients. In 2 eyes were improved and 1 eye was 
remained same. 
 ARMD was seen in 11 patients. In 9 eyes were improved and 2 eyes were 
remained same. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Conclusion 
 
CONCLUSION 
• Bevacizumab appears to be effective in the management of various retinal 
vascular diseases. 
• Improvement in best corrected visual acuity was statistically significant 
• The effect of Bevacizumab appears to be transient, necessitating repeat 
injections in case of recurrences. 
• Complication due to the procedure, such as vitreous hemorrhage and 
endophthalmitis are very rare. 
• Bevacizumab seems to be safe therapeutic option in patients who are resistant 
to conventional laser photocoagulation. 
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Proforma 
 
Role of Intravitreal Bevacizumab in the Management of Various Retinal Vascular 
Diseases 
Institute of Ophthalmology, Joseph Eye Hospital, Tiruchirapalli 
 
 Name :    Age:   Sex:  S.No 
 
 Address :       M.R. No.: 
         Retina No.: 
 
 Phone:        DOB: 
 Complaints: 
 
 Personal History: 
  
 Diabetes :  OHA / Insulin / Both / Nil 
 Hypertension 
 Dyslipidemia 
 Cardiac Status 
 Ocular Examination:  RE:  LE: 
   BCVA 
   IOP 
 
 
 Anterior Segment: 
   Cornea  Clear / Hazy  Clear / Hazy 
   Iris  NVI + / NVI –  NVI + / NVI – 
   Lens  Clear / IMM/ PCL Clear/IMM/PCL 
 Posterior Segment 
   PDR  CSME ±  CSME ± 
     NVD ±  NVD ± 
     NVE ±   NVE ± 
     Vit. Hge ±  Vit Hge ± 
   BRVO  Mac. Ede. ±  Mac. Ede. ±  
     NVD ±  NVD ± 
     NVE ±   NVE ± 
     Vit. Hge ±  Vit Hge ± 
   CRVO  Mac. Ede. ±  Mac. Ede. ±  
     NVD ±  NVD ± 
     NVE ±   NVE ± 
     Vit. Hge ±  Vit Hge ± 
   ARMD Mac. Ede. ±  Mac. Ede. ±  
     NVD ±  NVD ± 
     NVE ±   NVE ± 
     Vit. Hge ±  Vit Hge ± 
 Provisional Diagnosis: 
 
 Fundus Photograph:     Date: 
  FFA:   Date:   Findings: 
  
 
 
 
 OCT:  Date: 
    Macular Thickness 
    Macular Edema 
 Details of Intravitreal Bevacizuman ( Avastin) 
Follow up: 
 Duration BCVA IOP OCT Fundus 
Photograph 
FFA Regression of New vessels 
NVI / NVD / NVE/ VH 
3 days       
2 weeks       
4 weeks       
2nd month       
3rd month       
4th month       
5th month       
6th month       
 
 
 
  
 
 
 
 
Master Chart 
Click the Link Above 
Retina No BCVA BCVA (in Deci) ProDiag BCVA
BCVA 
(in Deci) BCVA
BCVA 
(in Deci) BCVA
BCVA 
(in Deci) BCVA
BCVA 
(in Deci) BCVA
BCVA 
(in Deci) BCVA
BCVA 
(in Deci) BCVA
BCVA 
(in Deci) BCVA
BCVA 
(in Deci) 
1 Vijayan 47 M 6146673    2273/07 1/60 0.02 PDR 1/60 0.02 2/60 0.03 2/60 0.03 2/60 0.03 2/60 0.03 2/60 0.03 2/60 0.03 2/60 0.03
2 Ramadoss 69 M 573932       871/2007 1/60 0.02 PDR 6/18 0.33 6/12 0.50 6/12 0.50 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67
3 Janaki Kandasamy 57 F
610326 /07     
1057/1999 5/60 0.08 PDR 6/36 0.17 6/36 0.17 6/36 0.17 6/36 0.17 6/36 0.17 6/36 0.17 6/36 0.17 6/36 0.17
4 Shakidullah 54 M 621135    2500/ 2007 1/60 0.02 PDR 1/60 0.02 1/60 0.02 1/60 0.02 1/60 0.02 1/60 0.02 1/60 0.02 1/60 0.02 1/60 0.02
5 Lakshmiammal 55 F 599656   1753/07 1/60 0.02 PDR 6/60 0.10 6/60 0.10 6/60 0.10 6/60 0.10 6/60 0.10 6/60 0.10 6/60 0.10 6/60 0.10
6 Baskar 40 M 597972   1269/07 2/60 0.03 PDR 1/60 0.02 1/60 0.02 6/36 0.17 6/24 0.25 6/24 0.25 6/6 1.00 6/6 1.00 6/6 1.00
7 Dhanalaxmi 59 F 580728   983/07 5/60 0.08 PDR 6/24 0.25 6/24 0.25 6/24 0.25 6/24 0.25 6/24 0.25 6/24 0.25 6/24 0.25 6/24 0.25
8 Punithavathy Paramasivam 61 F
574903    
39/2005 6/60 0.10 PDR 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67
9 Petchiammal 45 F 524645   1744/06  1/60 0.02 PDR 1/60 0.02 2/60 0.03 2/60 0.03 2/60 0.03 2/60 0.03 2/60 0.03 2/60 0.03 2/60 0.03
10 Chellammal 75 F 597223   1619/07  2/60 0.03 ARMD 2/60 0.03 2/60 0.03 2/60 0.03 2/60 0.03 2/60 0.03 2/60 0.03 2/60 0.03 2/60 0.03
11 Kalavathy 50 F 516542    1489/06  6/60 0.10 PDR 6/60 0.10 6/36 0.17 6/60 0.10 6/60 0.10 6/60 0.10 6/36 0.17 6/36 0.17 6/36 0.17
12 Antoniyammal 39 F 659277  5/60 0.08 BRVO 6/12 0.50 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67
13 Rengarajan 58 M 661902   951/08  6/24 0.25 PDR 5/60 0.08 6/18 0.33 6/60 0.10 6/60 0.10 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67
14 Siva Subramaniyan 49 M 644180 6/60 0.10 PDR 5/60 0.08 6/60 0.10 2/60 0.03 2/60 0.03 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67
15 Dharmalingam 52 M 635953   3014/07  1/60 0.02 PDR 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33
16 MsHametha 48 F 665218  5/60 0.08 PDR 6/60 0.10 6/18 0.33 6/18 0.33 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67
17 Leelavathi 60 F 666335   1137/08  6/60 0.10 ARMD 6/36 0.17 6/36 0.17 6/36 0.17 6/36 0.17 6/36 0.17 6/36 0.17 6/36 0.17 6/36 0.17
18 Tamilarasi 55 F 659726    851/08 5/60 0.08 PDR 6/24 0.21 6/24 0.21 6/24 0.21 6/24 0.21 6/24 0.21 6/24 0.21 6/24 0.21 6/24 0.21
19 MIyyavoo 53 M 543098   2408/06  5/60 0.08 PDR 6/24 0.25 6/24 0.25 6/24 0.25 6/24 0.25 6/24 0.25 6/24 0.25 6/24 0.25 6/24 0.25
20 Amanullah 58 M 644703     1542/08 3/60 0.05 PDR 5/60 0.08 5/60 0.08 5/60 0.08 5/60 0.08 5/60 0.08 5/60 0.08 5/60 0.08 5/60 0.08
21 Nirijah .P 58 F 531815   1989/06  6/60 0.10 CRVO 6/60 0.10 6/60 0.10 6/60 0.10 6/60 0.10 6/60 0.10 6/60 0.10 6/60 0.10 6/60 0.10
22 Aysha Beevi 70 F 674684   1488/08  2/60 0.03 CRVO 5/60 0.08 6/60 0.10 6/36 0.17 5/60 0.08 5/60 0.08 5/60 0.08 5/60 0.08 5/60 0.08
23 Natrajan 59 M 644634   299/08  5/60 0.08 ARMD 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50
24 Boopathy 48 M 568722   504/07 6/9 0.67 BRVO 6/6 1.00 6/6 1.00 6/6 1.00 6/6 1.00 6/6 1.00 6/6 1.00 6/6 1.00 6/6 1.00
25 Kannathal 55 F 643755  257/08  6/24 0.25 PDR 6/24 0.25 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33
Sno
Post injection 5 
month
Post injection 6 
month
Post injection 2 
month
Post injection 3 
month
Post injection 4 
month
Name
Post injection 2 
weeks
Post injection 1 
month
Age Sex
Pre Injection Post injection 3 days
26 Salma Beevi 55 F 647733   408/08  5/60 0.08 PDR 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33
Retina No BCVA BCVA (in Deci) ProDiag BCVA
BCVA 
(in Deci) BCVA
BCVA 
(in Deci) BCVA
BCVA 
(in Deci) BCVA
BCVA 
(in Deci) BCVA
BCVA 
(in Deci) BCVA
BCVA 
(in Deci) BCVA
BCVA 
(in Deci) BCVA
BCVA 
(in Deci) 
27 Thangammal 65 F 627699     2713/07  6/12 0.50 BRVO 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50
28 Abdul Alam 67 M 645364  314/2008 1/60 0.02 ARMD 5/60 0.08 5/60 0.08 5/60 0.08 5/60 0.08 5/60 0.08 5/60 0.08 5/60 0.08 5/60 0.08
29 Amirtham 54 F 604461   1895/07  5/60 0.08 ARMD 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67
30 Sundari 40 F 645825   337/2008  6/12 0.50 PDR 6/24 0.25 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67
31 Theresa mary 75 F 674185   1466/08 1/60 0.02 ARMD 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67
32 Vasuki 52 F 586645  5/60 0.08 PDR 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33
33 Hevani 46 F 665810   1121/08  6/36 0.17 PDR  6/36 0.17  6/36 0.17  6/36 0.17  6/36 0.17  6/36 0.17  6/36 0.17  6/36 0.17  6/36 0.17
34 Prema 60 F 674411    1473/08 1/60 0.02 PDR 6/9 0.67 6/6 1.00 6/6 1.00 6/6 1.00 6/6 1.00 6/6 1.00 6/6 1.00 6/6 1.00
35 Muthusamy 48 M 402645  6/9 0.67 PDR 5/60 0.08 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67
36 Raju 59 M 509900   1093/05  4/60 0.07 PDR 5/60 0.08 6/36 0.17 6/36 0.17 6/36 0.17 6/36 0.17 6/36 0.17 6/36 0.17 6/36 0.17
37 Sugirtha 39 F 679801   1710/08  3/60 0.05 PDR 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67
38 Radhakrishnan 70 M 680540   1743/08  4/60 0.07 ARMD 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67
39 Thangaraj 56 M 546475   2421/2005  2/60 0.03 PDR 6/6 1.00 6/6 1.00 6/6 1.00 6/6 1.00 6/6 1.00 6/6 1.00 6/6 1.00 6/6 1.00
40 Govindaraj 54 M 596274   1598/07  2/60 0.03 PDR 6/60 0.10 6/60 0.10 6/60 0.10 6/60 0.10 6/60 0.10 6/60 0.10 6/60 0.10 6/60 0.10
41 Suppanna 49 M 673652  1709/08 1/60 0.02 PDR 1/60 0.02 1/60 0.02 6/60 0.10 1/60 0.02 1/60 0.02 1/60 0.02 1/60 0.02 1/60 0.02
42 Mohanambal 71 F 677870    1631/08  6/60 0.10 ARMD 5/60 0.08 6/36 0.17 6/12 0.50 6/36 0.17 6/36 0.17 6/36 0.17 6/36 0.17 6/36 0.17
43 Charles 61 M 661567   936/08  6/60 0.10 PDR 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67
44 Thomas 62 M 663462    1027/08  6/60 0.10 PDR 1/60 0.02 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33
45 Karuppanna 57 M 412197  5/60 0.08 ARMD 6/18 0.33 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50
46 Dhevamani Pannerselvam 65 F
680921   
1763/08  6/60 0.10 ARMD 6/36 0.17 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33 6/18 0.33
47 Lakshmi 60 F 681319    1773/08 1/60 0.02 PDR 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67 6/9 0.67
48 Punitha 58 F 676061     1557 / 08  6/60 0.10 PDR 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50 6/12 0.50
49 Managalambal 66 F 673728   1446/08 1/60 0.02 ARMD 1/60 0.02 1/60 0.02 1/60 0.02 1/60 0.02 1/60 0.02 1/60 0.02 1/60 0.02 1/60 0.02
50 Anjalai 45 F 681701  1/60 0.02 CRVO 3/60 0.05 3/60 0.05 3/60 0.05 3/60 0.05 3/60 0.05 3/60 0.05 3/60 0.05 3/60 0.05
PDR - Diabetic Retinopathy
Sno Name Age Sex
Pre Injection Post injection 3 days
Post injection 2 
weeks
Post injection 1 
month
Post injection 6 
month
Post injection 2 
month
Post injection 3 
month
Post injection 4 
month
Post injection 5 
month
ARMD - Age Related Macular Degeneration
BRVO - Retinal Venous Occlusion
CRVO - Central Retinal Vein Occlusion
